Mantle Cell Lymphoma: what clinical progress in the last 5 years?

Mantle cell lymphomais still a lymphoma subtype with productive clinical research. Recent published data on Bruton kinase inhibitors have changed the managementof patients. This review summarizes the mostimportant trials evaluating the differenttreatment options in mantle cell lymphoma in the frontline and the relapsed/refractorysetting in young and older patients, focusing on the role of Bruton kinaseinhibitors in improving disease outcome and omitting consolidative autologous stemcell transplantation. Followingthe results of the TRIANGLE trial, the addition of ibrutinib to the inductionand maintenance treatment should be considered and the omission of autologousstem cell transplantation is questionable in all patients. Minimal residualdisease is a promising biomarker that would dictate our decision makingespecially in the maintenance setting. CAR-T cell remains the best option inthe relapsed/refractory patients after Brutonkinase inhibitors.